Abstract: An agent for modifying H.sub.2 O relaxation times in NMR diagnosis comprises a polysaccharide having chemically linked to it an organic complexant to which is complexed a paramagnetic metal ion. Polysaccharides include cellulose, starch, sepharose and dextran. Organic complexants include EDTA, DTPA and aminoethyl diphosphonate. A preferred metal ion is Gadolinium (III). The agents can be administered orally or parenterally.
Abstract: Patients having a predisposition for thrombus formation are effectively treated with compositions of acetylsalicylic acid, citric acid, thiamine and/or a zinc salt. The combination of aspirin and citric acid has been found to be significantly more effective in inhibiting platelet aggregability than aspirin alone, and thiamine contributes to the reduction in thrombotic potential by reducing plasma fibrinogen levels. Accordingly, new methods and compositions are disclosed for reducing the thrombotic potential of human or animal subjects, such as in the prophylaxis or treatment of atherosclerosis, vascular surgery patients or other cardiovascular diseases.
Type:
Grant
Filed:
April 22, 1993
Date of Patent:
March 28, 1995
Assignee:
The Hope Heart Institute
Inventors:
Lester R. Sauvage, Svetlana Kaplan, Alexander Kaplan
Abstract: A neuroprotecting drug comprises as an essential active ingredient ethyl 2-[4,5-bis(4-methoxyphenyl)thiazol-2-yl]pyrrol-1-yl acetate, which is useful with high safety for the prophylaxis and treatment of brain dysfunction induced by hypoxia due to the disturbance of cerebral circulation such as cerebral hemorrhage or cerebral infarction in human being.
Type:
Grant
Filed:
February 12, 1993
Date of Patent:
March 21, 1995
Assignee:
Kanebo, Ltd.
Inventors:
Noriko Yamamoto, Koichi Yokota, Akira Yamashita, Keizo Ito
Abstract: Methods for removing ferric iron from aqueous liquids and for performing deferration therapy are disclosed, involving the use of a novel siderophore, termed anguibactin. Anguibactin is isolated from a marine pathogen, Vibrio anguillarum, containing the pMJ1 plasmid. Anguibactin inhibits iron uptake by living cells, wrests iron from vertebrate tissues, removes iron from other siderophores and ferric hydroxide, and removes ferric iron from aqueous solutions, including cell-culture media. For deferration therapy, anguibactin from which bound iron has been removed is administered by dissolving in water or other liquid aqueous pharmaceutical carrier at a dosage typical for other siderophores. Anguibactin is preferably administered intramuscularly or subcutaneously, but can be given intravenously.
Type:
Grant
Filed:
November 15, 1990
Date of Patent:
February 28, 1995
Assignee:
State of Oregon Acting by and through the State Board of Higher Education on behalf of Oregon Health Sciences University
Abstract: The invention relates to a method for protecting the cerebral tissue of a human against the repercussions of ischaemia which comprises administering to a patient in need thereof a therapeutically effective amount of modafinil.
Abstract: A method for treating patients with rheumatoid arthritis comprises administering azaribine to the patient at a dosage level of 10 to 50 mg/kg/day for an initial period of from about 1 to about 3 weeks and then administering azaribine to the patient at dosage levels of at least 50 mg/kg/day and preferably at least 100 mg/kg/day.
Abstract: The present invention provides for a stabilized solution containing a halogen containing compound which is effective as a sterilizing or disinfecting agent, and a stabilizing agent which suppresses the chemical dissociation of the halogen compound such that the sterilizing capability of the solution is maintained for extended periods of time relative to the solution without the stabilizing agent. The halogen containing compound is selected from the group consisting of chlorine dioxide, bromine oxide, bromine chloride, monochloroamine, bromic acid, iodine monochloride, iodine trichloride and iodine monobromide. The stabilizing agent is a compound having at least one accessible sulphur containing group selected from the group consisting of cyclamic acid, dimethyl sulphoxide, glyoxyl sodium bisulphite, potassium sorbate, sodium cyclamate, sodium metabisulphite, sodium oxalate, sodium sulphite, sodium thiosulphate and thioacetamide.
Abstract: Alleviation of stomach ulcers in swine which are being administered exogenous somatotropin, by administering to the swine a benzimidazole compound selected from heterocyclylalkyl(sulfinyl or thio)benzimidazoles and [benzimidazolyl(sulfinyl or thio)alkyl]anilines.
Type:
Grant
Filed:
April 5, 1994
Date of Patent:
February 14, 1995
Assignee:
Monsanto Company
Inventors:
Clifton A. Baile, Frances C. Buonomo, Carol L. McLaughlin, Billy D. Vineyard
Abstract: This invention relates to the treatment of tachyarrhythmias of supraventricular origin. This condition may safely be treated by nasal administration of a composition comprising propranolol dissolved in a pharmaceutically acceptable, aqueous-based carrier. A total dose of up to 20 mg of propranolol may be administered at one time.
Abstract: This invention provides a method for treating patients to inhibit restenosis associated with coronary intervention. A 600 mg dosage of Tranilast for a treatment period of three consecutive months after coronary intervention lowers the incidence of restenosis, and reduces the degree of stenosis in patients.
Abstract: A medicinal composition comprising a practically water-insoluble anthelmintic compound such as PF1022 substance, which is a cyclic depsipeptide compound, as an active ingredient, and one or more compounds selected from either or both of nonionic surfactants and fats and oils, optionally together with one or more aqueous solvents, wherein the total content of the additives is adjusted to not less than 1 part by weight, preferably from 5 to 50 parts by weight, based on the anthelmintic compound. This composition makes it possible to elevate water-solubility of the anthelmintic comopund and thus enhance its anthelmintic effect.
Abstract: Mixtures of ethanol and monoglyceride are disclosed for enhancing the permeation of drugs through skin or mucosa. The monoglyceride is a monoglyceride or a mixture of monoglycerides of fatty acids with a total monoesters content of at least about 90%. Water is also included in the permeation-enhancing mixture.
Abstract: The present invention provides a new medical use for 3-[2-(dimethylamino)-ethyl]-N-methyl-1H-indole-5-methanesulphonamide and physiologically acceptable salts and solvates thereof in the treatment of tension-type headache and headache associated with substances or their withdrawal.
Abstract: This invention discloses a rapid-diffusion injectable formulation, comprising disulfiram or a suitable salt or analog of disulfiram. Unlike slow-release injectable formulations designed to ensure that chronic alcoholics have significant quantities of disulfiram in their blood at all time, the rapid-diffusion injectable formulation disclosed herein is designed to reduce the hypoxic or ischemic damage caused by crisis events such as stroke, heart attack, cardiac arrest, or asphyxiation. A rapid-diffusion injectable formulation can contain disulfiram mixed with water, an organic compound having a plurality of hydroxyl groups (such as pharmaceutically acceptable glycols or polysaccharides; propylene glycol, dextrans, and cyclodextrins are often used for such purposes), and a buffer.
Abstract: This invention relates to a method of treating fish diseases comprising administering a composition comprising a compound of the general formula: ##STR1## wherein R means an alkanoyl group; a benzoyl group optionally having 1 or more substituent groups selected the group consisting of lower alkyl groups and halogen atoms; a phenylacetyl group; or a cyclohexanecarbonyl group as an active ingredient. Also disclosed is administering a food supplemented with said compound to fish, and a fish food containing the same compound.
Abstract: Stable, aqueous detergent-iodine germicidal use compositions and concentrates adapted for application to animal or human skin are provided which have desirable detergent:iodine ratios of from about 2-4.5. The compositions and concentrates include a polyethoxylated polyoxypropylene block copolymer (poloxamer) as the complexing agent, wherein the polyoxypropylene moiety has an average molecular weight of at least 2600 and a polyoxyethylene content of from about 30%-75% by weight, in combination with from about 0.1%-5% by weight average available iodine on a nominal basis. Use of the defined class of poloxamers allows formulation of both high and low temperature stable compositions and concentrates. Other ingredients such as emollients, buffering agents and viscosity improvers can also form a part of the use compositions and concentrates.
Abstract: The invention provides a method of synchronizing farrowing in swine comprising the steps of administering an effective amount of a prostaglandin and then administering to the sows an effective amount of a peripheral .alpha..sub.2 adrenergic agonist, such that farrowing is induced.
Type:
Grant
Filed:
June 21, 1993
Date of Patent:
November 29, 1994
Assignee:
Iowa State University Research Foundation, Inc.
Abstract: A synergistic pharmaceutical composition of substituted phenoxy-, 1-, and 2-naphthalenyloxy-, indenyl-, indolyl-, benzo[b]furanyl-, and benzo[b]thienylcarboxamides of 7,8-(substituted-diamino)-1-oxaspiro[4.5]decanes and L-DOPA as a composition alleviating the symptoms of Parkinson's disease and/or dystonia. A method of using the pharmaceutical composition is also disclosed.
Abstract: A waste disposal landfill has at least one subsurface impermeable sheet for containing and directing fluid runoff from the site. This impermeable sheet can be remotely monitored with respect to its impermeability to verify that there are no breaks in the sheet and that no waste is passing therethrough.